Search
SWG Educational Activities
MeetingsSession on thrombocytopenias and platelet function disordersAt the EHA 2023 Congress, we held a session on ‘Thrombocytopenias and platelet function disorders: Recent developments and perspectives in immune thrombocytopenia.
Read moreTools and Overview Tables
EHA2023 session on COVID-19 and influenzaThe SWG suggested the above session, which was held during the EHA 2023 Hybrid Congress. Full titleCOVID-19 and influenza in patients with hematological malignancies.
Read morePublications
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D.
SWG Educational Activities
EICMLThe 2023 EICML meeting took place in Naples in May 2023. Fifty-five physicians and scientists met at the Palazzo Alabardieri in central Naples to spend two days discussing emerging data and developing collaborations.
Read moreEuropean Scientific foundation for Laboratory Hemato Oncology (ESLHO)
The objectives of ESLHO are to promote the continuous innovation and standardization of laboratory diagnostics focused on lymphoid malignancies, as well as to facilitate quality control and education in this field.
Read moreSWG Educational Activities
Recruitment trialsRecruitment is underway for the following trials:
Trial on precision hematology: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2); ClinicalTrials.
Curriculum-Exam Committee
Current committee members
Jose Tomás Navarro Ferrando, Spain (Chair)
Marielle Wondergem, The Netherlands (Vice-Chair and Progress test lead)
Alicia Rovó, Switzerland (Representative, Swiss Society)
Regular members
Gunnar Birgegård, Sweden
Roza Chaireti, Sweden
Carlos Fernández de Larrea, Spain
Mahesh Prahladan, United Kingdom
Ulla Wartiovaara-Kautto, Finland
AimTo promote harmonization in hematology training…
The ‘i4MDS’ consortium looks to the future at its second general meeting
The International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—also known as ‘i4MDS’—held its second general meeting in The Hague from February 9–10, 2024.
Read more‘i4MDS’ consortium wins prestigious EHA Innovation Grant
In a significant development, the International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—known as the ‘i4MDS’— has received an esteemed EHA Innovation Grant.
Read more